Teva Pharmaceutical Industries (TEVA) Exchange Rate Effect (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Exchange Rate Effect for 18 consecutive years, with -$17.0 million the latest figure, recorded in Q1 2026.

• Quarterly Exchange Rate Effect fell 137.78% year-over-year to -$17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$41.0 million (down 64.0% YoY) and the FY2025 annual result came in at $21.0 million, up 112.07% from the prior year.
• Exchange Rate Effect declined to -$17.0 million in Q1 2026 per TEVA's latest filing, from -$10.0 million in the prior quarter.
• Over the last five years, Exchange Rate Effect for TEVA reached as high as $146.0 million in Q4 2022 and fell as low as -$123.0 million in Q2 2022.
• A 5-year average of -$19.0 million and a median of -$17.0 million in 2026 frame the typical range for Exchange Rate Effect.
• The largest YoY upside for Exchange Rate Effect was 404.17% in 2022 against a maximum downside of 2360.0% in 2022.
• Year by year, Exchange Rate Effect stood at $146.0 million in 2022, then plunged by 53.42% to $68.0 million in 2023, then tumbled by 277.94% to -$121.0 million in 2024, then surged by 91.74% to -$10.0 million in 2025, then tumbled by 70.0% to -$17.0 million in 2026.
• According to Business Quant data, Exchange Rate Effect over the past three periods registered -$17.0 million, -$10.0 million, and -$9.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.